These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3892706)

  • 1. In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias.
    Raza A; Ucar K; Preisler HD; Mayers G
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):9-19. PubMed ID: 3892706
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.
    Raza A; Gezer S; Anderson J; Lykins J; Bennett J; Browman G; Goldberg J; Larson R; Vogler R; Preisler HD
    Exp Hematol; 1992 Nov; 20(10):1194-200. PubMed ID: 1426099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell kinetics in leukemia. Correlation with clinical features and response to chemotherapy.
    Vogler WR; Groth D; Garwood FA
    Arch Intern Med; 1975 Jul; 135(7):950-4. PubMed ID: 1080405
    [No Abstract]   [Full Text] [Related]  

  • 4. Studies on the cytotoxicity of cytosine arabinoside.
    Haanen C; Muus P; Raymakers R; Drenthe-Schonk A; Salden M; Wessels J
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):120-9. PubMed ID: 3892698
    [No Abstract]   [Full Text] [Related]  

  • 5. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
    Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928
    [No Abstract]   [Full Text] [Related]  

  • 6. Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation.
    Capizzi RL; Yang JL; Rathmell JP; White JC; Cheng E; Cheng YC; Kute T
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):65-74. PubMed ID: 3892704
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of early acute nonlymphatic leukemia with low dose cytosine arabinoside.
    Moloney WC; Rosenthal DS
    Haematol Blood Transfus; 1981; 26():59-62. PubMed ID: 7033074
    [No Abstract]   [Full Text] [Related]  

  • 8. [Principles of high-dose cytarabinoside treatment].
    Seeber S
    Onkologie; 1985 Feb; 8(1):4-7. PubMed ID: 3885120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Small doses of ARA-C in the treatment of myeloblastic leukemia and blast crisis of myelocytic leukemia].
    Górski J; Kicińska M; Cenian E
    Acta Haematol Pol; 1984; 15(3-4):167-70. PubMed ID: 6598941
    [No Abstract]   [Full Text] [Related]  

  • 10. Cellular and clinical pharmacology of low-dose ara-C.
    Kufe DW; Griffin JD; Spriggs DR
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):200-7. PubMed ID: 3925558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell cycle and drug sensitivity studies of leukemic cells that appear relevant in determining response to chemotherapy in acute nonlymphocytic leukemia.
    Raza A; Maheshwari Y; Mandava N; Yasin Z; Perveen S; Mayers G; Browman G; Goldberg J; Gottlieb A; Grunwald H
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):217-25. PubMed ID: 3589695
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cytosine-arabinoside in the treatment of acute leukemias].
    Böhnel J; Gingold N; Hermansky F; Pawlowski M; Stacher A
    Wien Med Wochenschr; 1972 Apr; 122(15):203-7. PubMed ID: 4527321
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose cytosine arabinoside in the treatment of resistant acute leukemia.
    Takaku F; Urabe A; Mizoguchi H; Yamada O; Wakabayashi Y; Miura Y; Sakamoto S; Yoshida M; Miwa S; Asano S
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):144-9. PubMed ID: 3859929
    [No Abstract]   [Full Text] [Related]  

  • 14. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.
    Keating MJ; Estey E; Plunkett W; Iacoboni S; Walters R; Kantarjian H; Andersson B; Beran M; McCredie KB; Freireich EJ
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):98-104. PubMed ID: 3859935
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug sensitivity test for patients with acute leukemia on high-dose ara-C therapy.
    Momparler RL; Onetto N; Momparler LF; Gyger M; Leclerc JM; Rivard GE
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):31-3. PubMed ID: 4012342
    [No Abstract]   [Full Text] [Related]  

  • 16. Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry.
    Lacombe F; Belloc F; Dumain P; Puntous M; Makhoul PC; Saux MC; Bernard P; Boisseau MR; Reiffers J
    Blood; 1994 Aug; 84(3):716-23. PubMed ID: 8043860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors.
    Burke PJ; Karp JE; Braine HG; Vaughan WP
    Cancer Res; 1977 Jul; 37(7 Pt 1):2138-46. PubMed ID: 266416
    [No Abstract]   [Full Text] [Related]  

  • 18. Arabinosyl cytosine in chronic myeloid leukaemia: evidence for high cytokinetic sensitivity of myeloblasts.
    Baccarani M; Santucci AM; Tura S; Killmann SA
    Scand J Haematol; 1976 May; 16(5):335-52. PubMed ID: 1065953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
    Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
    Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric determination with bromodeoxyuridine/DNA assay of sensitivity of S-phase cells to cytosine arabinoside in childhood acute lymphoblastic leukemia.
    Katano N; Tsurusawa M; Niwa M; Fujimoto T
    Am J Pediatr Hematol Oncol; 1989; 11(4):411-6. PubMed ID: 2618975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.